Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome.
about
Emerging pharmacologic treatment options for fragile X syndromeThe pathophysiology of fragile X (and what it teaches us about synapses)Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesTherapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and BackGenetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.Selective Disruption of Metabotropic Glutamate Receptor 5-Homer Interactions Mimics Phenotypes of Fragile X Syndrome in Mice.Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background.From FMRP function to potential therapies for fragile X syndrome.The autism diagnosis in translation: shared affect in children and mouse models of ASD.Genetic reduction of muscarinic M4 receptor modulates analgesic response and acoustic startle response in a mouse model of fragile X syndrome (FXS).Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome.Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxietyFragile X targeted pharmacotherapy: lessons learned and future directions.Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.Selective role of the catalytic PI3K subunit p110β in impaired higher order cognition in fragile X syndrome.Double Dissociation of the Roles of Metabotropic Glutamate Receptor 5 and Oxytocin Receptor in Discrete Social Behaviors.Synaptic plasticity in mouse models of autism spectrum disorders.Plasticity and mTOR: towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disordersDevelopment of mavoglurant and its potential for the treatment of fragile X syndrome.Synaptic basis of social dysfunction: a focus on postsynaptic proteins linking group-I mGluRs with AMPARs and NMDARs.The complex genetics in autism spectrum disorders.Pharmacotherapy for Fragile X Syndrome: Progress to Date.Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders.Altered Connectivity and Synapse Maturation of the Hippocampal Mossy Fiber Pathway in a Mouse Model of the Fragile X Syndrome.Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously.Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).Excess Translation of Epigenetic Regulators Contributes to Fragile X Syndrome and Is Alleviated by Brd4 Inhibition.Mdm2 mediates FMRP- and Gp1 mGluR-dependent protein translation and neural network activity.Sleep/wake physiology and quantitative EEG analysis of the Neuroligin-3 knockout rat model of autism spectrum disorder.Decreased home cage movement and oromotor impairments in adult Fmr1-KO mice.Protein synthesis levels are increased in a subset of individuals with Fragile X syndrome.Of Men and Mice: Modeling the Fragile X Syndrome.Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse model.
P2860
Q26829152-6493BF9B-9527-40A0-AF81-018E15386F2EQ27010675-5E8423E7-3969-462B-B88B-F301C487C5B9Q27023257-55ED89F4-00A4-4E52-8C5B-00E40CB369E4Q27337360-B151FD62-E64A-41C7-BCF8-124CA6815947Q28261563-A2A283D4-6BFB-4691-BB8A-6BD4F50E96AEQ30376422-73BBD8E1-BE3A-4EB1-A3B6-71DC6F7CE96DQ30403591-58788A5A-44CE-451F-8F33-8F5C1839BE2AQ30410502-29E92377-B544-4FE4-9568-8FB2396BCA5BQ30453436-39C2E7E8-033F-4ADE-8E0B-3EDFF11D27BFQ30457688-39348BE3-C332-44EB-A7CB-7CC129AC57E4Q30459497-AEB2D241-2823-4E1C-BC83-D137962F76D0Q30505749-4DC84EF9-4C0C-485F-8D2A-B76369FFB528Q30855390-AE66A335-3A3F-4225-BD3C-6D38DFB346A0Q33785983-140774E2-5D26-4732-8E34-9518B9687F2CQ34499370-927C3C77-E3AB-4D48-BCBD-4EE92AF0941AQ35588887-C5699113-8B7E-4A23-B4D9-B5C762AAC899Q35960336-15CF9220-FADD-414B-A21E-DB5522A31229Q36479094-C66482FD-2BCA-4071-B665-48126A8AB3AEQ38012453-AE8723B6-EB7F-421D-8D72-7B273CFD7BBEQ38164021-123EE47C-B779-4F20-98A5-1AE1BEC3EDFEQ38203028-3DBEDD25-77AB-4E06-BAE7-BC8D26518959Q38579867-3B45ACEA-C365-4148-B4E0-5A5B04A10D31Q38726962-67D1FE4F-00FB-4307-8851-9C99EF72549FQ39268882-61F5840C-2250-4127-90F3-C70075FDAEC5Q40376074-69E2877D-E0B0-4840-B533-DB1F96DFF037Q42512974-8D38943D-E0A0-42FD-A910-626EEC661133Q47112165-CB65DE9D-AA1B-4BE0-BCF4-7C12F59F98D4Q47118227-2B1296D9-C3DB-4632-B24F-E3D674757496Q47132107-15864495-2AA5-451C-929C-7D381CB2F411Q47601432-BFA99315-99CE-484C-BAC4-3537CE21F7AAQ47680079-949DDFD8-8616-4701-8567-B1FF0488A376Q47795409-B9AEE769-E2A6-45D4-9B96-42B9300E123DQ51733403-B25CD8F4-9EE6-4FAF-8E90-1668639E9C8BQ53422584-9A0967C5-4999-4FBD-8D99-851CDB5B7990Q55155951-2EEAE960-70DD-43E2-A79F-A63CCEE626AF
P2860
Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Genetic reduction of group 1 m ...... model for fragile X syndrome.
@ast
Genetic reduction of group 1 m ...... model for fragile X syndrome.
@en
type
label
Genetic reduction of group 1 m ...... model for fragile X syndrome.
@ast
Genetic reduction of group 1 m ...... model for fragile X syndrome.
@en
prefLabel
Genetic reduction of group 1 m ...... model for fragile X syndrome.
@ast
Genetic reduction of group 1 m ...... model for fragile X syndrome.
@en
P2093
P2860
P1476
Genetic reduction of group 1 m ...... model for fragile X syndrome.
@en
P2093
Alexia M Thomas
Deanna Graham
Jennifer R Perkins
Lisa A Yuva-Paylor
Nghiem Bui
Richard Paylor
P2860
P304
P356
10.1016/J.BBR.2011.04.049
P407
P577
2011-05-06T00:00:00Z